Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden. Shalabh Gupta, MD, Chief Execu

Related Keywords

United States ,Stockholm ,Sweden ,United Kingdom ,Satya Medicherla ,Shalabh Gupta ,Linkedin ,Youtube ,Exchange Commission ,European Renal Association ,Drug Administration ,Nasdaq ,Unicycive Therapeutics Inc ,Company Or Unicycive ,Reason Research ,Shire International Licensing ,Renal Associates ,Moral Administration ,Chief Executive Officer ,Urinary Phosphorous Reduction ,Comparative Study ,Oxylanthanum Carbonate ,Vice President ,Preclinical Pharmacology ,End Stage Kidney Disease ,Tolerability Trial ,Acute Kidney Injury ,Rat Model ,Delayed Graft ,End Stage Renal Disease ,Delayed Graft Function ,Graft Function ,Private Securities Litigation Reform Act ,Risk Factor ,Annual Report ,Kidney Disease ,Lc ,Oral Presentation ,Hyperphosphatemia ,Clinical Trials ,Cardiovascular Disease ,Biotechnology Company ,